Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Jan 2022
Price :
$35
*
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 10 Jan 2022 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI111430).
- 15 Sep 2020 Results comparing safety risks in clinical trials of PP3M and PP1M, presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology.
- 09 Oct 2013 Primary endpoint 'Positive-and-Negative-Syndrome-Scale' has been met according to results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.